Compare · GLP-1 agonist
Retatrutide vs Survodutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Retatrutide | Survodutide | |
|---|---|---|
| Evidence | Preliminary human | Preliminary human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational triple-hormone agonist with striking weight-loss data in trials, but not yet FDA-approved and with no peer-reviewed Phase 3 results. | An investigational GLP-1/glucagon dual agonist with solid placebo-controlled Phase 2 trials and one positive Phase 3 topline, but no approval and no peer-reviewed Phase 3 data. |
| Full profile → | Full profile → |
Retatrutide
Retatrutide (Lilly code LY3437943) is an investigational injectable drug for obesity and type 2 diabetes. It has produced some of the largest weight-loss figures seen in trials so far, but as of June 2026 it is not approved anywhere and its pivotal Phase 3 data have not yet been peer-reviewed.
Survodutide
Survodutide (development code BI 456906) is an investigational injectable drug being studied for obesity, fatty-liver disease, and type 2 diabetes. It has a stronger human evidence base than most peptides sold online, including several well-run placebo-controlled trials and one positive Phase 3…